|
|
|
| Study on comparison of medical expenses between hemodialysis and peritoneal dialysis in patients with end-stage renal disease |
| NIE Chen1 GAO Shuangqing2 CHEN Jinyu1 ZHANG Fang1 |
1.School of Business Administration, Shenyang Pharmaceutical University, Liaoning Province, Shenyang 110016, China;
2.Beijing Medical Health Economics Research Centre of North China, Beijing 100021, China |
|
|
|
Abstract Objective To investigate the direct medical expenses of hemodialysis and peritoneal dialysis in patients with end-stage renal disease in the real world and their influencing factors, so as to provide evidence support for policy formulation. Methods The data of dialysis patients in the urban insured patients database of China Health Insurance Research Association in 2015 was retrospectively analyzed. According to the inclusion and exclusion criteria, 2655 hemodialysis patients and 360 peritoneal dialysis patients were included. The 1∶1 propensity score matching method was used to balance the variables with imbalanced basic data between the groups and obtain matched patients, and multiple linear regression method was used to analyze the influencing factors of direct medical expenses. Results After propensity score matching, 584 dialysis patients were acquired, and the annual per capita direct medical expenses of hemodialysis were significantly higher than that of peritoneal dialysis (P ＜ 0.05). Multiple linear regression analysis showed that anemia, hypertension, dialysis mode, diabetes, regional and dyslipidemia were important factors affecting the direct medical expenses(P ＜ 0.05). Conclusion The direct medical expenses of peritoneal dialysis in patients with end-stage renal disease is lower than hemodialysis, the main influencing factors are complications and regions, in order to reduce the social and economic burden, payment mode should be adjusted to eliminate peritoneal dialysis fluid from drug proportion, promoting the promotion of peritoneal dialysis technology.
|
|
|
|
|
|
[1] 路文慧.终末期肾病患者的家庭护理负担研究进展[J].实用临床护理学杂，2018，46（3）：196.
[2] Masakane I，Taniguchi M，Nakai S，et al. Annual Dialysis Data Report 2015，JSDT Renal Data Registry [J]. Renal Replacement Therapy，2018，4（1）：1-99.
[3] Li KT，Kai MC. Peritoneal dialysis-first policy made successful：Perspectives and actions [J]. Am J Kidney Dis，2013，62（5）：993-1005.
[4] Wong B，Ravani P，Oliver MJ，et al. Comparison of Patient Survival Between Hemodialysis and Peritoneal Dialysis Among Patients Eligible for Both Modalities [J]. Am J Kidney Dis，2018，71（3）：344-351.
[5] Rivara MB，Mehrotra R. The changing landscape of home dialysis in the United States [J]. Curr Opin Nephrol Hypertens，2014，23（6）：586-591.
[6] Yang Y，Zhou X，Gao S，et al. Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China [J]. Drug Safety，2017，41（5）：1-13.
[7] 贺倩倩，张军锋.倾向评分匹配法在横断面资料处理中的应用价值研究[J].中国卫生统计，2018，35（3）：391-394.
[8] 马荣，朱辉，龚建平.基于倾向性评分匹配法的经导管肝动脉化疗栓塞联合高强度聚焦超声治疗肝癌的生存情况分析[J].中国癌症杂志，2018，28（4）：282-289.
[9] 陈金榆，高双庆，张方.基于医保数据分析我国2型糖尿病患者并发脑卒中的危险因素[J].中国药学杂志，2018， 53（10）：832-836.
[10] 吉俊，丁小强，滕杰，等.基层医院腹膜透析技术与管理专家共识[J].上海医学，2018，41（2）：68-72.
[11] 崔俊丹，周子琛，田庆丰，等.河南省终末期肾病透析患者疾病经济负担研究[J].医药论坛杂志，2017，38（10）：7-9，14.
[12] 郭武栋，刘莹，赵琨，等.基于7所三甲医院数据的血液透析成本测算与分析[J].中国医院管理，2018，38（2）：56-60.
[13] 王书会，刘芸宏，王静娜，等.血液透析住院患者医院感染经济负担调查[J].中华医院感染学杂志，2013，23（20）：4907-4908.
[14] 左力，刘雪丽，韩晟.肾性贫血加重中国慢性肾脏病患者经济负担的研究[J].中国药物经学，2018，13（9）：11-16.
[15] 倪兆慧，陈雅.贫血治疗的相关问题[J].中国血液净化，2014，13（6）：421-423.
[16] 杨晓玮，王荣.血液透析患者的贫血管理[J].中国血液净化，2018，17（1）：13-15.
[17] Beaudry A，Ferguson TW，Rigatto C，et al. Cost of Dialysis Therapy by Modality in Manitoba [J]. Clin J Am Soc Nephrol，2018，13（8）：1197-1203.
[18] 沈伟彬，文光慧.肾透析按人头付费医保门诊特殊病支付标准的研究[J].中国卫生标准管理，2018，9（15）：18-20.
[19] 范淑芳.腹膜透析患者自我效能与健康心理控制源的相关研究[J].天津护理，2017，25（6）：497-500. |
|
|
|
